| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 23, 2024 | VTRS Viatris Inc | Malik Rajiv61 | Director | Sell | 300,000 | $11.74 | $3,522,990.00 | -27.8% | +12.7% | -9.4% | |
| Aug 22, 2024 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,196 | $966.33 | $3,088,381.87 | - | -21.0% | -25.4% | |
| Aug 22, 2024 | CGC Canopy Growth Corp | Gedeon Christelle80 | See Remarks | Sell | 16,788 | $8.35 | $140,179.80 | -11.6% | -38.8% | -79.3% | |
| Aug 22, 2024 | ELAN Elanco Animal Health Inc | Harrington Michael J | Director | Buy | 3,500 | $14.85 | $51,974.30 | +4.5% | -8.0% | +22.6% | |
| Aug 22, 2024 | TXMD Therapeuticsmd, Inc. | Collins Cooper C. | - | Buy | 4,094 | $1.73 | $7,099.00 | +8.5% | -23.4% | -37.1% | |
| Aug 22, 2024 | CGC Canopy Growth Corp | Hong Judy Eun Joo65 | Chief Financial Officer | Sell | 50,188 | $8.35 | $419,069.80 | -21.2% | -38.8% | -79.3% | |
| Aug 22, 2024 | CGC Canopy Growth Corp | Klein David Eric55 | Chief Executive Officer | Sell | 40,135 | $8.35 | $335,127.25 | -10.0% | -38.8% | -79.3% | |
| Aug 21, 2024 | TXMD Therapeuticsmd, Inc. | Collins Cooper C. | - | Buy | 1,200 | $1.70 | $2,038.56 | +2.6% | -22.8% | -35.9% | |
| Aug 21, 2024 | UTHR United Therapeutics Corp | Causey Christopher59 | Director | Sell | 1,210 | $349.00 | $422,290.00 | -22.4% | +2.6% | -11.6% | |
| Aug 21, 2024 | LNTH Lantheus Holdings, Inc. | Thrall James H | Director | Sell | 1,000 | $98.52 | $98,520.00 | -2.8% | -21.5% | -41.6% | |
| Aug 21, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $348.08 | $2,506,194.30 | -22.5% | +2.6% | -11.6% | |
| Aug 20, 2024 | PRGO Perrigo Co Plc | Andersen Svend47 | EVP &President Chci | Sell | 34,983 | $27.69 | $968,560.28 | -17.8% | -3.3% | -14.9% | |
| Aug 20, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,334 | $16.71 | $39,001.14 | -1.4% | +27.0% | +162.4% | |
| Aug 19, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,828 | $329.02 | $2,575,568.56 | -52.6% | +3.0% | -10.1% | |
| Aug 19, 2024 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 211 | $1.95 | $410.61 | -0.1% | +13.2% | +7.4% | |
| Aug 19, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 3,600 | $344.18 | $1,239,047.37 | -8.6% | +3.0% | -10.1% | |
| Aug 16, 2024 | PCRX Pacira Biosciences, Inc. | Brege Laura62 | Director | Buy | 1,000 | $12.81 | $12,810.00 | +6.0% | +26.5% | +91.5% | |
| Aug 16, 2024 | PCRX Pacira Biosciences, Inc. | Bigal Marcelo82 | Director | Buy | 1,512 | $13.25 | $20,034.00 | +17.5% | +26.5% | +91.5% | |
| Aug 16, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 472 | $15.66 | $7,391.52 | -13.9% | +33.8% | +195.4% | |
| Aug 16, 2024 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 7,200 | $322.00 | $2,318,396.95 | -30.0% | +20.3% | -2.4% | |
| Aug 15, 2024 | NBIX Neurocrine Biosciences Inc | Rastetter William H48 | Director | Sell | 14,250 | $146.69 | $2,090,332.50 | -27.5% | -15.1% | -10.1% | |
| Aug 15, 2024 | AMRX Amneal Pharmaceuticals, Inc. | Boyer Andrew S | Executive Vice President | Sell | 62,711 | $7.84 | $491,381.91 | -10.2% | +14.2% | +19.5% | |
| Aug 14, 2024 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel55 | See Remarks | Sell | 2,500 | $97.54 | $243,850.00 | -3.1% | -10.3% | -42.6% | |
| Aug 14, 2024 | AMRX Amneal Pharmaceuticals, Inc. | Shah Nikita53 | Executive Vice President | Sell | 100,000 | $7.75 | $775,000.00 | -25.5% | +18.4% | +20.2% | |
| Aug 14, 2024 | PCRX Pacira Biosciences, Inc. | Yang Michael J. | Director | Buy | 2,000 | $12.90 | $25,800.00 | +38.2% | +34.7% | +100.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.